An unexpected impurity, incomplete safety data or a question about chemical exposure can disrupt a development programme just as a submission deadline approaches. For pharmaceutical, biotechnology and medical device companies, risk assessment in toxicology is often the step that determines whether an identified concern can be resolved using existing evidence or whether further investigation is needed.

The difficulty is rarely limited to identifying a potential hazard. Companies must fully characterize that hazard, establish exposure estimates and calculate the risk related to this particular hazard. Choosing an assessment route too quickly may lead to unnecessary testing, additional costs or a report that still leaves the central safety question unanswered.

This makes how to choose a provider for toxicology risk assessment a practical business decision, not simply a search for someone to prepare a technical document. At Billev Pharma East, our toxicology consultancy helps companies define the problem, make sense of available evidence and develop a scientifically justified strategy suited to the product and its regulatory context. Our aim is to replace uncertainty with clear next steps, without recommending work that does not add meaningful value.

What should companies do before selecting a toxicology risk assessment provider?

Before approaching an external expert, companies should be able to explain the safety question they need answered and the decision that depends on it. This may involve qualification of a pharmaceutical impurity, an unexpected degradation product, potential mutagenicity, or the safety of chemicals released from a medical device. A clearly defined scope makes risk assessment in toxicology more focused and helps the provider propose an appropriate methodology.

The next priority is to collect the evidence already available. Analytical reports, substance identity and composition, manufacturing information, existing toxicological studies, scientific literature and exposure assumptions may each affect the conclusion. For medicines, patient dose and treatment duration can be important. For medical devices, the nature and duration of body contact and relevant chemical characterisation data are central. Even when information is incomplete, identifying its limitations early is preferable to assuming that more testing is automatically required.

Companies should also consider the applicable framework before finalising the assessment. For example, the evaluation of potentially mutagenic pharmaceutical impurities is addressed by ICH M7(R2), whereas ISO 10993-17 provides a framework for toxicological risk assessment of medical device constituents. These are different questions and should not be treated as interchangeable.

An experienced provider should therefore begin by understanding the product, reviewing the evidence and explaining which gaps genuinely affect the safety decision. That initial discussion can save time later and give the project a more reliable starting point.

How can Billev Pharma East help with risk assessment in toxicology?

At Billev Pharma East, we support companies when a toxicological issue is slowing progress or when the available data do not yet provide a convincing basis for a safety decision. Our risk assessment in toxicology services combine scientific interpretation with regulatory understanding, allowing clients to address the question behind the assessment rather than simply commission another report.

Our team supports toxicological evaluation of impurities, degradation products and nitrosamines, as well as questions involving mutagenicity, genotoxicity, systemic toxicity and other relevant endpoints. For medical devices, we help manufacturers assess chemical constituents, extractables and leachables and develop biological safety documentation aligned with applicable ISO 10993 requirements and the EU MDR. We can also support wider nonclinical planning and regulatory documentation where a project requires it.

Our approach follows five practical stages: identify the safety question and its regulatory context; assess hazards, exposure and available evidence; integrate studies, scientific literature, in silico predictions or read-across where appropriate; justify the conclusions and outstanding data needs; and document a clear, traceable scientific rationale. The sequence helps clients see how each piece of evidence contributes to the decision. When testing is needed, we can work with qualified laboratory partners while maintaining independent interpretation of the results.

Clients work with us because they need an expert who can explain the implications of the data and propose a realistic way forward. We provide clear recommendations and scientifically reasoned documentation so internal teams can make decisions with greater confidence and approach regulatory discussions better prepared.

How to choose a provider for toxicology risk assessment

For companies researching how to choose a provider for toxicology risk assessment, the first question should be whether the provider has experience with the particular product and safety concern. A pharmaceutical impurity assessment, a nonclinical safety question and a medical device extractables evaluation can require different data, assumptions and regulatory references. General toxicology knowledge alone may not be enough to resolve a specialised issue.

It is also worth asking how the provider works with incomplete evidence. A sound approach should distinguish a genuine information gap from information that can be addressed through literature, existing studies, read-across or an appropriately selected predictive method. The provider should be able to explain why a specific approach is suitable, where it is limited and what would justify further testing. This is particularly important when the decision affects cost or project timing.

The final report deserves just as much attention as the scientific method. Strong risk assessment in toxicology documentation explains the substances and exposures considered, the data relied upon, the treatment of uncertainty and the reasoning behind the conclusion. It should be written for its intended use, whether that is an internal development decision or a regulatory submission.

Finally, the working relationship matters. Look for a partner who asks useful questions at the start, communicates clearly as evidence develops and remains focused on the decision you need to make. That is the type of practical scientific support Billev Pharma East aims to provide.

What should companies expect from a toxicology risk assessment provider?

A reliable toxicology provider should do more than deliver a technical report. Companies should expect a clearly defined assessment scope, an approach suited to the relevant product and exposure scenario, and conclusions that answer the original safety question. The deliverable needs to be useful to development, quality and regulatory teams, not only to a toxicologist.

At the beginning of the project, the provider should explain what data will be reviewed, which assumptions will be necessary and how any gaps could influence the outcome. This can be especially important for complex impurities, uncertain exposure estimates or chemical constituents with limited published safety information. Timely communication about emerging findings helps companies plan decisions without waiting until the final report.

The completed assessment should document the evidence considered, the methods used, the relevant uncertainties and the scientific basis for any recommended limits, testing or controls. Companies should also know whether support is available if a regulatory authority or notified body asks for further clarification.

Billev Pharma East brings this decision-focused approach to risk assessment in toxicology. We help clients understand what existing data can establish, what remains unresolved and which next step offers meaningful scientific value. The result is a documented safety assessment with practical implications for the project, not simply a compilation of toxicology findings.

What should a comprehensive risk assessment in toxicology include?

A comprehensive toxicological evaluation connects hazard information with a realistic understanding of exposure. It should identify the substance or constituent being evaluated, determine which adverse effects are relevant, estimate the extent of exposure and explain whether the resulting risk is acceptable for the intended use. Simply listing toxicological study results does not answer that question.

The initial review typically covers substance identity, available experimental studies, published evidence and endpoints relevant to the exposure scenario. The assessment may consider mutagenicity, systemic toxicity, reproductive or developmental toxicity, or other endpoints where justified. The route, frequency and duration of exposure are then examined, as these can materially influence the interpretation of a hazard.

The scientific rationale must also be transparent about uncertainties. In some cases, a suitable health-based reference value or exposure threshold can inform the risk characterisation. In others, limited data may call for an expert weight-of-evidence evaluation or further work. A credible assessment explains why a method was selected, what information supports its use and which limitations remain.

For companies, the most useful deliverable is a report that provides an understandable conclusion and an actionable recommendation. Billev Pharma East helps translate analytical and toxicological information into coherent scientific documentation that supports the next product development or regulatory decision.

When is risk assessment in toxicology needed for impurities and degradation products?

An unexpected impurity or degradation product can prompt questions about patient exposure, acceptable limits and the adequacy of existing controls. Risk assessment in toxicology is particularly relevant when available information does not establish whether the substance is adequately qualified for its intended exposure or when a regulator requests further justification. Importantly, detection of an impurity does not automatically establish an unacceptable patient risk.

For pharmaceuticals, the assessment depends on the type of impurity and the applicable guidance. ICH Q3A and Q3B address relevant aspects of impurities in new drug substances and products, while ICH M7(R2) provides a specific approach to DNA-reactive mutagenic impurities. Depending on the circumstances, other established guidance may be relevant to residual solvents, elemental impurities or nitrosamine concerns. Applying the correct framework prevents unrelated hazards from being evaluated using a single generic method.

Exposure is central to the scientific argument. The impurity level, maximum daily dose, route of administration and duration of use can affect the conclusion. Existing toxicological information may be sufficient in some cases; in others, further evaluation or an appropriate control strategy is necessary.

Billev Pharma East supports clients in reviewing impurity data, evaluating relevant endpoints, interpreting exposure and preparing toxicological justifications. Our focus is on answering the specific regulatory safety question and helping companies determine proportionate next steps rather than treating every detected impurity as a reason for new testing.

How does toxicological risk assessment support medical device biological safety?

For medical devices, risk assessment in toxicology can be necessary to understand the health implications of chemical constituents that may reach the patient or user during intended use. These may include material-related substances, processing residues, extractables or leachables. The assessment should be integrated with the device’s overall biological evaluation rather than considered as an isolated exercise.

ISO 10993-17:2023 describes requirements and methods for toxicological risk assessment of medical device constituents, while ISO 10993-18 addresses chemical characterisation. The relevance of any identified substance depends on factors including its identity, potential released quantity, nature of contact and duration of exposure. The assessment may be informed by chemical analytical results, compositional information and existing toxicological evidence.

A common challenge is determining whether the available chemical information is sufficiently reliable to support a conclusion. Testing methods, analytical uncertainties and exposure estimates need to be interpreted in light of the intended use of the finished device. Additional biological testing is not automatically the most useful response to every open question.

Billev Pharma East assists manufacturers with the toxicological component of biological safety assessment, evaluation of extractables and leachables, gap identification and supporting biological evaluation documentation. We help connect chemical evidence to a reasoned safety conclusion suitable for the applicable medical device regulatory context.

Can risk assessment in toxicology reduce unnecessary testing and development costs?

Yes, a well-designed toxicological evaluation can reveal when available evidence is sufficient and when further work will genuinely improve a safety decision. That distinction matters because new studies require time, resources and careful planning. Commissioning tests before the underlying question has been defined may produce additional data without resolving the issue that prompted the assessment.

Published literature, existing studies, carefully selected predictive methods and read-across can sometimes provide a scientific basis for evaluating a substance. For certain pharmaceutical impurities, ICH M7(R2) recognises appropriate (Q)SAR-based approaches to assessing mutagenic potential. However, no method should be used mechanically: its applicability, limitations and consistency with the other evidence must be examined before a conclusion is drawn.

A good assessment may also identify a more focused data need. Rather than requesting a broad testing package, the team may need to clarify an exposure assumption, improve chemical identification or obtain information on a particular toxicological endpoint. That can make subsequent work more relevant and easier to justify.

At Billev Pharma East, we review the available evidence before recommending the next step. Our aim is not to minimise testing at any cost, but to ensure that the selected approach adequately protects safety while avoiding work with little scientific or regulatory value. This helps clients invest resources where they are most useful.

Choose Billev Pharma East for expert risk assessment in toxicology

Choosing the right provider means choosing a team that can make complex toxicological information useful for real development and regulatory decisions. Reliable risk assessment in toxicology should answer the safety question, explain the underlying evidence and establish what happens next.

At Billev Pharma East, we combine toxicological expertise with regulatory insight to support pharmaceutical, biotechnology and medical device companies facing impurity concerns, incomplete safety evidence or biological safety questions. We tailor our work to the product and the decision at hand, with a clear emphasis on scientific justification, proportionate investigation and practical recommendations.

Need a reliable partner for your toxicological assessment? Contact Billev Pharma East to discuss your specific challenge and find out how our specialists can help turn an unresolved safety concern into a clear assessment plan.

Frequently asked questions

Sources: 1 – European Medicines Agency (EMA). ICH M7(R2) – Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, 2 – International Council for Harmonisation (ICH). ICH Q3A(R2) – Impurities in new drug substances, 3 – International Organization for Standardization (ISO). ISO 10993-17:2023 – Biological evaluation of medical devices – Part 17: Toxicological risk assessment of medical device constituents, 4 – International Organization for Standardization (ISO). ISO 10993-18:2020 – Biological evaluation of medical devices – Part 18: Chemical characterization of medical device materials within a risk management process, 5 – European Parliament and Council. Regulation (EU) 2017/745 on medical devices (EU MDR).